А. Г. Чучалин
Pirogov Russian National Research Medical University · 546 works · 11,622 citations · h-index 41
Top works
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma
- Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation
- Genome-wide Association Study Identifies Genetic Variation in Neurocan as a Susceptibility Factor for Bipolar Disorder
- HERMES: a European Core Syllabus in Respiratory Medicine
- MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation
- Integrated care pathways for airway diseases (AIRWAYS-ICPs)
- MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
- Genome-wide association study reveals two new risk loci for bipolar disorder
- ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
- A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma
- Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction
- A review of national guidelines for management of COPD in Europe
- Influence of N -acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
- Lung function and asthma control with beclomethasone and formoterol in a single inhaler
- Development and implementation of guidelines in allergic rhinitis – an ARIA‐GA2LEN paper
- Prioritised research agenda for prevention and control of chronic respiratory diseases
- A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison
- Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
- Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of SeretideTM (50/250 μg bd DiskusTM vs. formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via TurbuhalerTM) in patients with moderate-to-severe asthma